4/25/2012

A second late-stage trial showed that Biogen Idec's oral drug candidate BG-12 significantly reduced relapse and additional brain lesions in patients with relapsing-remitting multiple sclerosis over two years compared with placebo. Glatiramer acetate was used as a reference comparator. BG-12 also demonstrated safety and tolerability.

Related Summaries